GO
Loading...

Novartis AG

More

  • A 'tattoo' may end fingerpricks for diabetics Thursday, 15 Jan 2015 | 11:56 AM ET
    Joseph Wanf

    Scientists have developed a glucose monitor that is about as invasive as a rub-on tattoo.

  • US STOCKS-Wall St flat in volatile trade after Swiss move Thursday, 15 Jan 2015 | 11:03 AM ET

    *Bank of America, Citi down after results. NEW YORK, Jan 15- U.S. stocks were little changed in choppy trading on Thursday, as investors wrestled with the ramifications with a move by the Swiss National Bank to scrap its three-year euro cap on the franc. Swiss stocks traded in the U.S. moved higher, Credit Suisse, up 0.7 percent at $22.98 and Novartis, up 1.9 percent to...

  • US STOCKS-Wall St drops after Swiss move; banks tumble Thursday, 15 Jan 2015 | 9:56 AM ET

    *Bank of America, Citi down after results. NEW YORK, Jan 15- U.S. stocks fell, erasing small gains at the open on Thursday, as investors grappled with a move by the Swiss National Bank to scrap its three-year euro cap on the franc. Swiss stocks traded in the U.S. moved higher, including UBS, up 2.4 percent at $16.87, Credit Suisse, up 3.2 percent at $23.55 and Novartis, up 1.9...

  • *Bank of America falls after results. *Best Buy down after holiday sales. Swiss stocks traded in the U.S. moved higher before the opening bell, including UBS, up 3.6 percent at $17.07, Credit Suisse, up 4 percent at $23.72 and Novartis, up 3.8 percent to $100.48, as a strengthening Swiss franc made U.S.-dollar denominated stocks cheaper.

  • Swiss large-caps lose $100B on currency move Thursday, 15 Jan 2015 | 8:45 AM ET

    The Swiss franc soared—and Swiss stocks tanked—as that country's central bank shocked markets Thursday with a move to scrap a cap against the euro.

  • *Bank of America falls in premarket after results. *Best Buy down in premarket after holiday sales. *Swiss stocks traded in the U.S. moved higher in premarket trading, including UBS, up 7 percent at $17.45, Credit Suisse, up 3.9 percent at $23.70 and Novartis, up 7 percent to $103.63.

  • *Asset could be worth up to 2 bln euros- Bloomberg. FRANKFURT, Jan 15- German drugmaker Boehringer Ingelheim said it is considering the sale of its U.S.-based generics unit Roxane Labs to put a stronger focus on the development and sale of new pharmaceuticals. A company spokeswoman said Boehringer was not a specialist in generics and was therefore considering...

  • Jan 7- A panel to the U.S. Food and Drug Administration unanimously backed the approval of Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen, setting the stage for the regulator's first approval of a biosimilar. The biosimilar could be priced at the same level as Neupogen, but cost to insurers and consumers would be lower, Novartis executives...

  • Jan 7- A panel to the U.S. Food and Drug Administration unanimously backed the approval of Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen, paving the way for the regulator's first approval for a biosimilar. The injectable biologic, Neupogen, prevents infections in breast cancer patients undergoing chemotherapy, which reduces their white...

  • Jan 7- Eli Lilly and Co, which has been battered in the past three years by competition from generics, forecast 2015 earnings and revenue just shy of Wall Street expectations. Lilly, which is betting on its rejuvenated pipeline of drugs, particularly for diabetes, oncology and animal health, forecast adjusted 2015 earnings of $3.10 to $3.20 per share.

  • LONDON, Jan 6- Vectura Group, a respiratory drugs specialist, will work with Janssen Biotech to develop treatments for asthma and lung disease COPD, it said on Tuesday. Janssen, a unit of Johnson& Johnson, will then use Vectura's dry powder inhaler technologies in the development of inhaled therapeutics for airways-related diseases such as asthma, a market worth...

  • Midday movers: Exxon Mobil, Chevron, Hess & more Monday, 5 Jan 2015 | 12:56 PM ET

    Some of Monday's midday movers:

  • Jan 5- Staff reviewers at the U.S. Food and Drug Administration recommended approval for Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen. Novartis's drug is the first to be reviewed in the United States under the so-called biosimilar pathway. The reviewers recommended that Novartis's copy should be approved for all the five indications...

  • Jan 5- Staff reviewers at the U.S. Food and Drug Administration recommended approval for Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen. Novartis's drug is the first to be reviewed in the United States under the so-called biosimilar pathway. The reviewers recommended that Novartis's copy should be approved for all the five indications...

  • Early movers: CVEO, YHOO, NVS, GM, CLF & more Friday, 2 Jan 2015 | 7:45 AM ET
    NYSE exchange floor

    Some of the names on the move ahead of the open.

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • Early Movers: WAG, GMCR, CHK, JPM & more Tuesday, 23 Dec 2014 | 8:08 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • After-hours buzz: P&G, Vanda, Steelcase & more Monday, 22 Dec 2014 | 5:32 PM ET

    Check out which companies are making headlines after the bell Monday: P&G, Vanda, Steelcase & more.

  • LONDON, Dec 18- Shareholders in British drugmaker GlaxoSmithKline have approved a planned deal with Switzerland's Novartis, which will see the two pharmaceutical groups trade more than $20 billion of assets. The transaction, which includes GSK buying Novartis' vaccines business, Novartis purchasing GSK's cancer drugs, and the two groups tying up in consumer...